Zydus Lifesciences Ltd on Wednesday reported a profit of Rs 1023.80 crore during the third quarter of FY25, posting a growth of 29.66 per cent in comparison to Rs 789.60 crore recorded during the same period of FY24.
It posted revenue from operations at Rs 5269.10 crore, up 16.96 per cent as against Rs 4505.20 crore during the third quarter of previous financial year. The company EBITDA was up 26 per cent YoY at Rs 1,387 crore.
“We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability. Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations,” Dr Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said.
The company posted Capex (organic) for the quarter at Rs. 290.7 crore. Zydus Life said that its Research & Development (R&D) investments for the quarter stood at Rs 503.10 crore (9.5% of revenues).
In the Formulation Business, the company registered revenues of Rs. 1498.2 crore, up 5% y-o-y. The business accounted for 29 percent of consolidated revenues.
According to the company’s statement, the business grew faster than the market with 8% y-o-y secondary sales growth. Chronic segment outpaced the market growth driving the overall performance of the business (Source: IQVIA Oct – Dec 2024 qtr).
During the first nine months of the fiscal, the business grew by 9% outpacing the market growth.
“Portfolio of innovation products sustained the growth momentum and continued to deliver strong volume growth. Gained market share in key therapies of Cardiology, Respiratory, Anti-infectives and super specialty therapy of Oncology. On the super specialty front, continued to strengthen leadership position in Nephrology and Oncology therapies,” the company stated.
Moreover the share of chronic portfolio has increased consistently over last several years and stood at 42.4%, which is an improvement of 370 bps over the last 3 years, as per IQVIA MAT December 2024 data.
The company’s Consumer Wellness business registered revenues of Rs. 448.8 crore, up 13 % y-o-y with 4.8% volume growth. The business accounted for 9 percent of revenues. Personal care segment witnessed strong demand and achieved robust double-digit growth. The segment has continued its upward trajectory over the last several quarters.
The US formulations business registered revenues of Rs. 2409.6 crore, up 31% y-o-y and flat q-o-q. The business accounted for 47% of consolidated revenues. International Markets formulations business registered revenues of Rs. 570.2 crore, up 16% YoY. The business accounted for 11% of consolidated revenues.
